Sweet and Sassy Franchising vs HealthSource Chiropractic

HealthSource Chiropractic is the stronger software-sales opportunity right now, and it comes down to budget and terrain. The AUV advantage of nearly $58,000 per unit signals healthier operator cash flow and a greater willingness to invest in tools that drive efficiency or patient acquisition. That budget strength is amplified by an approved-supplier procurement model, which means we can sell directly to franchisees without getting strangled by a corporate gatekeeper. The sheer scale—129 units versus 16—gives us a real TAM to build pipeline density and a reference base, even with slight negative unit growth. A shrinking system is a risk, but it also creates urgency: operators under pressure need POS and marketing automation that demonstrably lifts revenue, and we can position precisely against that pain.

Sweet and Sassy’s 36% unit growth is the shiny object here, but it’s a trap. With only 15 franchised units and a franchisor-controlled procurement model, we’d be locked into a single-threaded corporate sale that can kill our cycle time and margin, all for a tiny TAM. The 10% ad fund is a red herring—that money goes to brand marketing, not to unit-level software budgets. Worse, the overdue FDD filing signals operational distraction at the franchisor level, which makes a top-down partnership even less likely to close quickly. The growth rate is impressive on a percentage basis, but it’s growth off a near-zero base, and it doesn’t translate into enough at-bats to justify the terrain disadvantage.

The meaningful tradeoff is TAM and procurement freedom versus growth momentum. HealthSource gives us a large, directly addressable base of operators with the budget to buy and the autonomy to decide. Sweet and Sassy offers a fast-growing but tiny, locked-down system that would consume disproportionate sales effort for minimal total contract value. We take the mature, open system with real budget every time.

Verdict: HealthSource Chiropractic wins on budget, terrain, and TAM, making it the superior near-term revenue play despite negative unit growth.